Simeprevir gets CHMP backing

EMA's CHMP backed approval of Olysio simeprevir from Johnson & Johnson (NYSE:JNJ) to treat HCV genotypes 1 and 4 infection in adults in combination with other drugs, including interferon and ribavirin. J&J already markets the second-generation HCV NS3/4A protease inhibitor in the U.S. as Olysio, in Canada as Galexos and in Japan as Sovriad to treat chronic HCV genotype 1 infection in combination with interferon and ribavirin in patients with compensated liver disease. ...